CMA

Comerica Stock Jumps 3.0% – Potential for Further Growth?

Comerica stock is trading -10.14% below its average target price of $59.35 after marking a 3.0% during today's morning session. Analysts are giving the Mid-Cap Banking company an average rating of buy and target prices ranging from $52.0 to $68.0 per share.

The stock has an average amount of shares sold short at 5.0%, and a short ratio of 2.86. Only 0.78% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 82.3% of Comerica's shares being owned by this investor type.

Institutions Invested in Comerica

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 13% 16,878,129 $900,110,650
2023-12-31 Blackrock Inc. 9% 11,823,522 $630,548,449
2023-12-31 State Street Corporation 5% 7,145,780 $381,084,460
2023-12-31 First Trust Advisors LP 3% 4,507,700 $240,395,649
2023-12-31 Alliancebernstein L.P. 3% 3,456,189 $184,318,565
2023-12-31 Charles Schwab Investment Management, Inc. 3% 3,343,131 $178,289,182
2023-12-31 Invesco Ltd. 3% 3,329,635 $177,569,440
2023-12-31 Morgan Stanley 2% 3,045,114 $162,395,935
2023-12-31 Geode Capital Management, LLC 2% 3,005,229 $160,268,868
2023-12-31 Dimensional Fund Advisors LP 2% 2,605,943 $138,974,944

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Comerica.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS